Colorectal Cancer | Unmet Need | US/EU | 2018
The treatment paradigm for second- and subsequent-line advanced or metastatic colorectal cancer revolves around targeted agents (such as Erbitux, Vectibix, and Avastin) with or without chemotherapy regimens. The 2017 FDA approvals of Keytruda and Opdivo have expanded treatment options for the minority of patients with MSI-H or dMMR metastatic colorectal cancer. Although the market landscape is evolving at a rapid pace, significant unmet need exists for the development of well-tolerated agents that can improve overall survival and progression-free survival outcomes.
Questions Answered
- What are the treatment drivers that are most likely to influence a therapy’s uptake for second- and subsequent-line advanced or metastatic colorectal cancer?
- How do current therapies perform on key treatment drivers and goals for second- and subsequent-line advanced or metastatic colorectal cancer?
- What are the prevailing areas of unmet need and hidden opportunities in this patient population?
- What trade-offs are surveyed medical oncologists willing to make across different key clinical attributes and price, when considering hypothetical new treatment options in the second-line setting?
Product Description
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, and the United Kingdom.
Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in March 2018.
Key companies: Roche/Genentech, Eli Lilly/Merck KGaA, Amgen, Taiho Pharmaceutical, Merck & Co., and Bristol-Myers Squibb.
Key drugs: Avastin, Erbitux, Vectibix, Lonsurf, Keytruda, and Opdivo.
